Barclays PLC Acquires 39,506 Shares of Harrow, Inc. (NASDAQ:HROW)

Barclays PLC lifted its holdings in shares of Harrow, Inc. (NASDAQ:HROW) by 301.9% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 52,593 shares of the company’s stock after purchasing an additional 39,506 shares during the period. Barclays PLC’s holdings in Harrow were worth $2,365,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Mirae Asset Global Investments Co. Ltd. raised its position in Harrow by 21.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,283 shares of the company’s stock worth $57,000 after acquiring an additional 227 shares during the period. The Manufacturers Life Insurance Company increased its stake in shares of Harrow by 5.0% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 11,865 shares of the company’s stock worth $248,000 after purchasing an additional 567 shares during the last quarter. Quest Partners LLC bought a new stake in shares of Harrow in the 3rd quarter worth approximately $29,000. nVerses Capital LLC purchased a new position in Harrow in the second quarter valued at approximately $33,000. Finally, Allspring Global Investments Holdings LLC grew its holdings in Harrow by 2,730.7% during the second quarter. Allspring Global Investments Holdings LLC now owns 2,123 shares of the company’s stock valued at $44,000 after purchasing an additional 2,048 shares during the period. 72.76% of the stock is owned by hedge funds and other institutional investors.

Harrow Trading Down 0.5 %

NASDAQ:HROW opened at $33.83 on Thursday. Harrow, Inc. has a 1 year low of $9.13 and a 1 year high of $59.23. The stock’s fifty day moving average price is $43.82 and its two-hundred day moving average price is $37.01. The company has a debt-to-equity ratio of 3.23, a current ratio of 1.55 and a quick ratio of 1.44. The company has a market cap of $1.20 billion, a P/E ratio of -35.99 and a beta of 0.69.

Analysts Set New Price Targets

HROW has been the topic of several research reports. Craig Hallum boosted their target price on Harrow from $45.00 to $65.00 and gave the company a “buy” rating in a research note on Friday, October 4th. B. Riley lowered their price objective on Harrow from $73.00 to $69.00 and set a “buy” rating on the stock in a research note on Wednesday, December 4th. Finally, Lake Street Capital increased their target price on shares of Harrow from $45.00 to $55.00 and gave the stock a “buy” rating in a research report on Friday, October 4th.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.